The Role of Kinases in Neurodegenerative Diseases: From Pathogenesis to Treatment
Authors:
- BadruddeenBABadruddeen
- Anas IslamAIAnas Islam
- 4 June 2025
- journal article
- review article
- Published by Wiley in European Journal of Neuroscience
- Vol. 61 (11) , e70156
Abstract
Neurodegenerative diseases are characterized by progressive neuronal loss and dysfunction, with protein kinases playing crucial roles in their pathogenesis. This article explores the involvement of protein kinases in these disorders, focusing on their contributions to disease mechanisms, potential as therapeutic targets and challenges in developing effective treatments. In Alzheimer's disease, kinases such as CDK5, GSK3β and MARK4 are implicated in tau hyperphosphorylation and the formation of neurofibrillary tangles. Kinases also regulate amyloid‐β processing and plaque formation. In Parkinson's disease, LRRK2, PINK1 and other kinases contribute to α‐synuclein pathology, mitochondrial dysfunction and neuroinflammation. LRRK2 inhibitors and PROTACs have shown promise in preclinical models. Huntington's disease involves altered kinase activity, with CK2, GSK3 and MAPK pathways influencing mutant huntingtin toxicity and aggregation. Kinases are also implicated in less common neurodegenerative diseases, such as ALS and spinocerebellar ataxias. Despite the therapeutic potential of targeting kinases, challenges remain, including the complexity of kinase networks, blood–brain barrier permeability and the lack of robust biomarkers. Emerging technologies, such as covalent inhibitors, targeted protein degradation and combination therapies, offer new avenues for addressing these challenges and developing more effective treatments for neurodegenerative diseases.Keywords
This publication has 123 references indexed in Scilit:
- Tau and neurodegenerationCytoskeleton, 2023
- Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseasesJournal of Cellular Biochemistry, 2023
- LRRK2‐Targeting Therapies March Through the Valley of DeathMovement Disorders, 2023
- LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?Movement Disorders, 2022
- Apoptosis and its therapeutic implications in neurodegenerative diseasesClinical Anatomy, 2021
- Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseasesAlzheimer's & Dementia, 2021
- Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's DiseaseMovement Disorders, 2020
- Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson DiseaseJAMA Neurology, 2020
- Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer DiseaseJAMA Neurology, 2019
- Protein kinases CK1 and CK2 as new targets for neurodegenerative diseasesMedicinal Research Reviews, 2011